TherapeuticsMD, Inc. (NASDAQ:TXMD) stock is sliding down and has lost 1.64%, with over 79K shares traded. It opened at $1.22. At 9:35 is trading at $1.205.
TherapeuticsMD Submits NDA to FDA For BIJUVA’s Variant
TherapeuticsMD submitted a supplemental New Drug Application (sNDA) for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg, to the U.S. Food and Drug Administration (FDA).
FDA is expected to respond to the application within 74 days
BIJUVA is a novel combination of bio-identical estradiol and bio-identical progesterone in a once-daily oral softgel capsule. BIJUVA is approved in the U.S. in a 1mg/100mg strength for the treatment of moderate to severe vasomotor symptoms due to menopause in women with a uterus.
BIJUVA is the only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule.
Conclusion
TXMD has been moving higher the last 12 sessions. It may be headed for a breakout. The pivot points to watch out for is 1.224 1.227 1.234 above and 1.204 1.207 1.214 below.
The RSI-14 days has been a positive for the stock at 59.82. The stock is trading higher than its 50, 200 day moving averages of 1.1867 and 1.3788 respectively.
 Is Moving Towards A New Low?){kind=link}